Illumina, Inc. $ILMN Shares Bought by NorthCrest Asset Manangement LLC

NorthCrest Asset Manangement LLC grew its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 75.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 11,296 shares of the life sciences company’s stock after purchasing an additional 4,871 shares during the period. NorthCrest Asset Manangement LLC’s holdings in Illumina were worth $1,597,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently made changes to their positions in the business. MassMutual Private Wealth & Trust FSB raised its holdings in shares of Illumina by 7.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,081 shares of the life sciences company’s stock worth $142,000 after purchasing an additional 79 shares in the last quarter. Assetmark Inc. lifted its stake in Illumina by 10.2% during the third quarter. Assetmark Inc. now owns 1,039 shares of the life sciences company’s stock valued at $99,000 after purchasing an additional 96 shares during the last quarter. Versant Capital Management Inc boosted its holdings in Illumina by 8.9% during the third quarter. Versant Capital Management Inc now owns 1,364 shares of the life sciences company’s stock worth $130,000 after buying an additional 111 shares in the last quarter. Archer Investment Corp boosted its holdings in Illumina by 12.9% during the third quarter. Archer Investment Corp now owns 1,073 shares of the life sciences company’s stock worth $102,000 after buying an additional 123 shares in the last quarter. Finally, Callan Family Office LLC grew its position in Illumina by 4.4% in the third quarter. Callan Family Office LLC now owns 2,939 shares of the life sciences company’s stock worth $279,000 after buying an additional 124 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have issued reports on ILMN shares. Zacks Research cut Illumina from a “strong-buy” rating to a “hold” rating in a report on Wednesday, December 31st. Wall Street Zen raised Illumina from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 14th. Stifel Nicolaus lifted their target price on Illumina from $135.00 to $155.00 and gave the stock a “buy” rating in a report on Tuesday, January 20th. Robert W. Baird set a $137.00 target price on Illumina in a report on Friday, February 6th. Finally, JPMorgan Chase & Co. cut their target price on Illumina from $130.00 to $120.00 and set a “neutral” rating on the stock in a research report on Friday, February 6th. Six equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $129.69.

Insider Activity

In other news, SVP Patricia Leckman sold 2,370 shares of the stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total value of $275,346.60. Following the completion of the sale, the senior vice president owned 16,321 shares in the company, valued at $1,896,173.78. This represents a 12.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 2.60% of the stock is owned by insiders.

Illumina Stock Down 0.4%

ILMN stock opened at $123.79 on Tuesday. Illumina, Inc. has a 52-week low of $68.70 and a 52-week high of $155.53. The company’s 50 day simple moving average is $130.48 and its 200-day simple moving average is $121.14. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.08 and a quick ratio of 1.72. The firm has a market capitalization of $18.93 billion, a P/E ratio of 22.71, a P/E/G ratio of 2.38 and a beta of 1.45.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, February 5th. The life sciences company reported $1.35 EPS for the quarter, beating the consensus estimate of $1.26 by $0.09. Illumina had a net margin of 19.57% and a return on equity of 31.04%. The business had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.10 billion. During the same quarter in the prior year, the firm earned $0.95 EPS. The firm’s quarterly revenue was up 5.0% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. As a group, equities research analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current year.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.